296 related articles for article (PubMed ID: 20040315)
1. Anderson-Fabry disease: developments in diagnosis and treatment.
Mehta AB
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
[TBL] [Abstract][Full Text] [Related]
2. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
3. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
4. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
6. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts.
Spada M; Baron R; Elliott PM; Falissard B; Hilz MJ; Monserrat L; Tøndel C; Tylki-Szymańska A; Wanner C; Germain DP
Mol Genet Metab; 2019 Mar; 126(3):212-223. PubMed ID: 29785937
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous complications of Anderson-Fabry disease.
Giuseppe P; Daniele R; Rita BM
Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
[TBL] [Abstract][Full Text] [Related]
8. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
9. Gastroenterological complications of Anderson-Fabry disease.
Buda P; Książyk J; Tylki-Szymanska A
Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
[TBL] [Abstract][Full Text] [Related]
10. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.
Das AM; Naim HY
Adv Clin Chem; 2009; 49():57-71. PubMed ID: 19947355
[TBL] [Abstract][Full Text] [Related]
11. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
12. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.
El Dib R; Gomaa H; Ortiz A; Politei J; Kapoor A; Barreto F
PLoS One; 2017; 12(3):e0173358. PubMed ID: 28296917
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
15. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.
Hoffmann B
Orphanet J Rare Dis; 2009 Oct; 4():21. PubMed ID: 19818152
[TBL] [Abstract][Full Text] [Related]
17. [Priapism: a severe paediatric complication of Fabry disease].
Labarthe F; de Bodman C; Maruani A; Szwarc C; Froissart R; Lorette G; Lardy H
Rev Med Interne; 2010 Dec; 31 Suppl 2():S217-9. PubMed ID: 21211667
[TBL] [Abstract][Full Text] [Related]
18. Anderson Fabry disease: a multiorgan metabolic disease susceptible of treatment.
Tuttolomondo A
Curr Pharm Des; 2013; 19(33):5972-3. PubMed ID: 23448458
[No Abstract] [Full Text] [Related]
19. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
